AstraZeneca: Enhertu DESTINY-PanTumor02 Shows Positive Results
6/3 08:24
(RTTNews) - British drug maker AstraZeneca Plc (AZN, AZN.L) and Daiichi Sankyo (DSKYF.PK) announced Monday that Enhertu (trastuzumab deruxtecan) in DESTINY-PanTumor02 Phase II trial showed clinically meaningful and durable responses across multiple HER2-expressing tumour types....